Lamivudine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LAMIVUDINE |
|---|---|
| Type | Drug |
| Aliases | 3TCEpivirHeptodinZeffixЛамівудин |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-AASLD-HBV-2024 |
Drug Facts
| Class | Nucleoside reverse transcriptase inhibitor (NRTI); HBV polymerase inhibitor |
|---|---|
| Mechanism | Cytosine analog phosphorylated intracellularly to lamivudine triphosphate, which competes with dCTP for incorporation into HBV DNA / HIV RNA — leading to chain termination. Active against both HIV and HBV. For HBV: lamivudine has been largely supplanted by entecavir, tenofovir DF, and tenofovir AF due to high rates of resistance (~70% at 5 years). Retains role in resource-limited settings, post-transplant prophylaxis, and as part of HIV ART. |
| Typical dosing | HBV: 100 mg PO once daily. HIV (as part of ART): 150 mg PO BID OR 300 mg PO once daily (always combined with other antiretrovirals). Renal adjustment: CrCl 30-49: 100 mg first dose, then 50 mg daily (HBV) CrCl 15-29: 100 mg first, then 25 mg daily CrCl 5-14: 35 mg first, then 15 mg daily CrCl <5 / dialysis: 35 mg first, then 10 mg daily |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-05-18 |
Warnings
- Lactic acidosis and severe hepatomegaly with steatosis (class effect of NRTIs)
- Post-treatment exacerbations of hepatitis B if discontinued — monitor LFTs and HBV-DNA closely after stopping
- Different formulations for HIV vs HBV — risk of HIV resistance if HBV-strength lamivudine used as HIV monotherapy in unrecognized HIV-HBV coinfection (always screen HIV before HBV monotherapy)
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. Older HBV antiviral largely superseded by entecavir and tenofovir AF/DF due to high resistance rates (~70% at 5 years monotherapy). Retains role in: HIV ART (combined with other agents), post-liver-transplant HBV prophylaxis (combined with HBIg, then often switched to entecavir/tenofovir), resource-limited settings. NEVER use lamivudine monotherapy for HIV (rapid resistance). HBV reactivation prophylaxis: prefer entecavir or tenofovir AF over lamivudine for rituximab/anti-CD20 use.
Used By
No reverse references found in the YAML corpus.